UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.162

Sortiert nach

Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review

Arthritis research & therapy, 2021-06, Vol.23 (1), p.1-168, Article 168

2021

Volltextzugriff (PDF)

Prevalence of chronic urticaria and healthcare usage of patients with the condition in primary care: a population-based study in the Netherlands

British journal of dermatology (1951), 2024-01, Vol.190 (2), p.287-289

2024

Volltextzugriff (PDF)

Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis: A Step Toward Personalized Treatment

JAMA dermatology (Chicago, Ill.), 2015-06, Vol.151 (6), p.616

2015

Volltextzugriff (PDF)

Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2020-04, Vol.156 (4), p.393

2020

Volltextzugriff (PDF)

Trends in three major histological subtypes of cutaneous melanoma in the Netherlands between 1989 and 2016

International journal of dermatology, 2023-04, Vol.62 (4), p.508-513

2023

Volltextzugriff (PDF)

Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry

JAMA dermatology (Chicago, Ill.), 2022-09, Vol.158 (9), p.1048

2022

Volltextzugriff (PDF)

Resorption of the calcium phosphate layer on S53P4 bioactive glass by osteoclasts

Journal of materials science. Materials in medicine, 2019-08, Vol.30 (8), p.94-13, Article 94

2019

Volltextzugriff (PDF)

Association of HLA-C06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis

JAMA dermatology (Chicago, Ill.), 2019-06, Vol.155 (6), p.708

2019

Volltextzugriff (PDF)

Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients

Pediatric allergy and immunology, 2021-05, Vol.32 (4), p.720-726

2021

Volltextzugriff (PDF)

Blood-Based Immune Profiling Combined with Machine Learning Discriminates Psoriatic Arthritis from Psoriasis Patients

International journal of molecular sciences, 2021-10, Vol.22 (20), p.10990

2021

Volltextzugriff (PDF)

Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up

JAMA dermatology (Chicago, Ill.), 2014-02, Vol.150 (2), p.130

2014

Volltextzugriff (PDF)

Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study

Trials, 2021-10, Vol.22 (1), p.707-707, Article 707

2021

Volltextzugriff (PDF)

Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks

Acta dermato-venereologica, 2023-10, Vol.103, p.adv17752-adv17752

2023

Volltextzugriff (PDF)

Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three‐year follow‐up data of a single‐blind randomized controlled trial

Journal of the European Academy of Dermatology and Venereology, 2023-09, Vol.37 (9), p.1815-1824

2023

Volltextzugriff (PDF)

Effectiveness and Safety of Systemic Therapy for Psoriasis in Older Adults: A Systematic Review

JAMA dermatology (Chicago, Ill.), 2020-11, Vol.156 (11), p.1229

2020

Volltextzugriff (PDF)

Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID)

The Journal of dermatological treatment, 2023-12, Vol.34 (1), p.2161297-2161297

2023

Volltextzugriff (PDF)

Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial

The Journal of dermatological treatment, 2022-07, Vol.33 (5), p.1-2684

2022

Volltextzugriff (PDF)

Should we prefer biologics over nonbiological agents in psoriasis?

British journal of dermatology (1951), 2023-08, Vol.189 (3), p.258-259

2023

Volltextzugriff (PDF)

Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab

British journal of dermatology (1951), 2022-12, Vol.187 (6), p.1028-1030

2022

Volltextzugriff (PDF)

Randomized clinical trial of laparoscopic versus open inguinal hernia repair

British journal of surgery, 1999-03, Vol.86 (3), p.316-319

1999

Volltextzugriff (PDF)

Immunomodulatory aged neutrophils are augmented in blood and skin of psoriasis patients

Journal of allergy and clinical immunology, 2021-10, Vol.148 (4), p.1030-1040

2021

Volltextzugriff (PDF)

Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls

Journal of investigative dermatology, 2015-07, Vol.135 (7), p.1-5

2015

Volltextzugriff (PDF)

Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis

Drugs (New York, N.Y.), 2024-05, Vol.84 (5), p.565-578

2024

Volltextzugriff (PDF)

How to define a ‘super-responder’ to biologics in psoriasis studies

British journal of dermatology (1951), 2023-10, Vol.189 (5), p.621-622

2023

Volltextzugriff (PDF)

Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial

BMC dermatology, 2017-05, Vol.17 (1), p.6, Article 6

2017

Volltextzugriff (PDF)

1 – 25 von 1.162

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.026)
Mit Volltextzugriff
(943)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(829)
Life Sciences & Biomedicine
(700)
Humans
(604)
Female
(349)
Male
(344)
Adult
(230)
Biological And Medical Sciences
(224)
Middle Aged
(208)
Medical Sciences
(176)
Aged
(133)
Adolescent
(126)
Medicin Och Hälsovetenskap
(124)
Endocrinology & Metabolism
(113)
Animals
(103)
Child
(100)
Physical Sciences
(89)
Fundamental And Applied Biological Sciences. Psychology
(70)
Pediatrics
(65)
Physics
(65)
Surgery
(64)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(17)

Menü

Weitere Dienste

Einstellungen

Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review

Prevalence of chronic urticaria and healthcare usage of patients with the condition in primary care: a population-based study in the Netherlands

Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis: A Step Toward Personalized Treatment

Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial

Trends in three major histological subtypes of cutaneous melanoma in the Netherlands between 1989 and 2016

Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry

Resorption of the calcium phosphate layer on S53P4 bioactive glass by osteoclasts

Association of HLA-C06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis

Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients

Blood-Based Immune Profiling Combined with Machine Learning Discriminates Psoriatic Arthritis from Psoriasis Patients

Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up

Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study

Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks

Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three‐year follow‐up data of a single‐blind randomized controlled trial

Effectiveness and Safety of Systemic Therapy for Psoriasis in Older Adults: A Systematic Review

Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID)

Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial

Should we prefer biologics over nonbiological agents in psoriasis?

Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab

Randomized clinical trial of laparoscopic versus open inguinal hernia repair

Immunomodulatory aged neutrophils are augmented in blood and skin of psoriasis patients

Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls

Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis

How to define a ‘super-responder’ to biologics in psoriasis studies

Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial

Suchergebnisse filtern